Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164630 | 0.93 | ACLY (0.42) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5166577 | 0.88 | ALDH1A1 (0.41) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5164817 | 0.86 | PTPN1 (0.42) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5164531 | 0.86 | NR1H2 (0.40) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5167005 | 0.85 | NR1H2 (0.42) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5165866 | 0.85 | PTPN1 (0.48) | ACLYALDH1A1PTPN1 | |
| SCHEMBL5163077 | 0.85 | LMNA (0.40) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5166039 | 0.84 | ALDH1A1 (0.43) | NR1H2NR1H3ALDH1A1TAS2R14PTPN1 | |
| SCHEMBL5166081 | 0.82 | NR1H2 (0.37) | ACLYNR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5167311 | 0.82 | NR1H2 (0.39) | ACLYNR1H2NR1H3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | ACLY 3966/4885NR1H2 4860/4885NR1H3 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.